As cancer drug prices rise, it remains unclear whether the cost of new interventions is
related to their beneficial impact for patients at a societal-level. Using data for 2003–2015 …

Background Countries with similar health systems but different medicines policies might
result in substantial medicines usage differences and resultant outcomes. The literature is …

Although the last two decades have seen the healthcare systems of most developed
countries face pressure for major reform, the impact of this reform on the relationship …

The world faces a worsening public health crisis: A growing number of bacteria are resistant
to available antibiotics. Yet there are few new antibiotics in the development pipeline to take …

Policy space can be defi ned in different ways depending on context. In this chapter we
focus on policy space defi ned as the freedom, scope, and mechanisms that governments …

This issue brief reviews the evidence on the impact of price controls on biopharmaceutical
innovation and calibrates what this evidence implies for recent price control proposals in the …

Introduction: Patients' access to medicines can be profoundly affected by the decisions
made by medicine licensing bodies and public reimbursement agencies. The present study …

Significant changes have occurred in Australia's national primary healthcare (PHC) policy
over the last decade, but little assessment has been made of implications for equity. This …

The authors provide evidence that firms can enhance their own objectives by internalizing
the objectives of most stakeholder groups. This suggests that society's objectives, as defined …

Abstract A National Stakeholders' Meeting on Quality use of Medicines to Optimise Ageing in
Older Australians was held in Sydney 2015 with the aim of setting an agenda to improve the …